Clinical Trials Logo

Clinical Trial Summary

Helipyl is on the market; actually it is a post-biotic because it is a killed Lactobacillus reuteri DSMZ 17648. The aim is to demonstrate (or not) that this product eradicates helicobacter, which it claims to do.


Clinical Trial Description

This is a pilot project. There is quite limited literature on this product and Helicobacter pylori eradication. My personal opinion is that the literature and guidelines are contradictory. The European guideline is that Helicobacter pylori should not be corrected unless there are "serious" symptoms . On the other hand, Helicobacter is a carcinogen. Quite often, parents ask us, children's gastroenterologists, to screen their children for Helicobacter because they are symptomatic and are being eradicated, and know that Helicobacter is contagious. This creates a difficult situation: not answering the question is not an option according to the parents' opinion. Going into the question and eradicating "classic" is against all guidelines. Hence this pilot project: 10 complaints-free carriers of Helicobacter pylori (> 5 years) will be treated with Helipyl for one month (product supplied by the company). Beforehand, at the end of the treatment and a month after stopping of the treatment, we do a C13 breath test. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04618159
Study type Interventional
Source Universitair Ziekenhuis Brussel
Contact
Status Completed
Phase Phase 4
Start date February 10, 2019
Completion date January 25, 2020

See also
  Status Clinical Trial Phase
Completed NCT00596401 - The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Not yet recruiting NCT02934048 - Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Phase 4
Not yet recruiting NCT05586464 - Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine Phase 1